HL Financial Services LLC bought a new stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 1,363 shares of the biopharmaceutical company’s stock, valued at approximately $669,000.
Other hedge funds have also made changes to their positions in the company. National Pension Service increased its stake in shares of Regeneron Pharmaceuticals by 10.8% in the second quarter. National Pension Service now owns 66,518 shares of the biopharmaceutical company’s stock valued at $33,920,000 after buying an additional 6,481 shares during the last quarter. Grandfield & Dodd LLC increased its stake in shares of Regeneron Pharmaceuticals by 1.1% in the first quarter. Grandfield & Dodd LLC now owns 1,497 shares of the biopharmaceutical company’s stock valued at $580,000 after buying an additional 17 shares during the last quarter. Highbridge Capital Management LLC acquired a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter valued at $323,000. Princeton Capital Management Inc. increased its stake in shares of Regeneron Pharmaceuticals by 6.7% in the first quarter. Princeton Capital Management Inc. now owns 2,496 shares of the biopharmaceutical company’s stock valued at $967,000 after buying an additional 157 shares during the last quarter. Finally, CIBC World Markets Inc. increased its stake in shares of Regeneron Pharmaceuticals by 2,190.6% in the first quarter. CIBC World Markets Inc. now owns 21,784 shares of the biopharmaceutical company’s stock valued at $8,442,000 after buying an additional 20,833 shares during the last quarter. Hedge funds and other institutional investors own 66.70% of the company’s stock.
Regeneron Pharmaceuticals, Inc. (REGN) opened at 466.59 on Friday. Regeneron Pharmaceuticals, Inc. has a 12-month low of $325.35 and a 12-month high of $543.55. The company has a market capitalization of $49.47 billion, a price-to-earnings ratio of 46.81 and a beta of 1.66. The firm’s 50-day moving average price is $495.54 and its 200 day moving average price is $426.50.
Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported $4.17 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.67 by $1.50. The company had revenue of $1.47 billion for the quarter, compared to analysts’ expectations of $1.36 billion. Regeneron Pharmaceuticals had a net margin of 22.05% and a return on equity of 25.58%. The business’s revenue was up 21.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.82 EPS. On average, analysts expect that Regeneron Pharmaceuticals, Inc. will post $14.84 earnings per share for the current year.
ILLEGAL ACTIVITY WARNING: This news story was first reported by Stock Observer and is the sole property of of Stock Observer. If you are accessing this news story on another domain, it was stolen and reposted in violation of U.S. and international copyright and trademark law. The legal version of this news story can be accessed at https://www.thestockobserver.com/2017/08/12/hl-financial-services-llc-buys-new-position-in-regeneron-pharmaceuticals-inc-nasdaqregn.html.
Several research firms have commented on REGN. Vetr cut Regeneron Pharmaceuticals from a “sell” rating to a “strong sell” rating and set a $368.84 price target for the company. in a report on Monday, May 15th. Robert W. Baird cut Regeneron Pharmaceuticals from a “neutral” rating to an “underperform” rating and set a $408.00 price target for the company. in a report on Tuesday, August 1st. Zacks Investment Research cut Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 4th. Credit Suisse Group cut Regeneron Pharmaceuticals to a “hold” rating and set a $485.00 price target for the company. in a report on Friday, July 14th. Finally, Canaccord Genuity set a $522.00 price target on Regeneron Pharmaceuticals and gave the company a “buy” rating in a report on Friday, July 28th. Two research analysts have rated the stock with a sell rating, fourteen have issued a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average price target of $489.35.
In related news, major shareholder Sanofi acquired 136,050 shares of the business’s stock in a transaction dated Friday, June 2nd. The shares were bought at an average price of $478.17 per share, with a total value of $65,055,028.50. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, SVP Michael S. Aberman sold 2,269 shares of the stock in a transaction dated Thursday, June 22nd. The stock was sold at an average price of $532.42, for a total transaction of $1,208,060.98. Following the transaction, the senior vice president now directly owns 9,193 shares in the company, valued at approximately $4,894,537.06. The disclosure for this sale can be found here. Insiders have sold a total of 56,922 shares of company stock worth $27,383,105 in the last three months. Insiders own 10.40% of the company’s stock.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.